Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH,

(Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has commenced dosing in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical study of ALT …, (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has commenced dosing in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical study of ALT …, Read More

Scroll to Top